(2020) A future COVID-19 vaccine is being developed at unprecedented speed to augment immune system defenses. This paper presents myriad infection/vaccine-related mechanisms that could adversely impact vaccine effectiveness and safety.
SARS-CoV-2 relies on the non-structural protein Nsp1 for multiplication within the host cells and disarms the host immune defences by various mechanisms. Research highlights the importance of artemisinin and its derivatives in the development of drugs to inhibit SARS-CoV-2 Nsp1 protein
Autoimmune hepatitis episodes have been described following SARS-CoV-2 infection and vaccination but their pathophysiology remains unclear. Here, we report the case of a 52-year-old male, presenting with bimodal episodes of acute hepatitis, each occurring 2-3 weeks after BNT162b2 mRNA vaccination and sought to identify the underlying immune correlates. The patient received first oral budesonide, relapsed, but achieved remission under systemic steroids.
In this report, we describe 2 cases of myocardial inflammation temporally associated with receipt of a COVID-19 mRNA vaccine in patients without evidence of concurrent or prior COVID-19 infection.
Myopericarditis following mRNA Covid-19 vaccination predominately occur in younger adult men within 14 days following the second dose. This story has a 56 yo man after 4 months vax, with troponin I level elevated and Cardiac Magnetic Resonance showed a pattern of acute myocarditis.
